Trial · NCT01175668
Clonidine for Neonatal Abstinence Syndrome Study
NCT01175668, Not applicable, Terminated, Baystate Medical Center; results first posted 2014-01-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clonidine for Neonatal Abstinence Syndrome Study. Trials, record NCT01175668. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01175668
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clonidine for Neonatal Abstinence Syndrome Study
- NCT number
- NCT01175668
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 68 participants, actual
- Lead sponsor
- Baystate Medical Center
- Conditions
- Neonatal Abstinence Syndrome
- Interventions
- Clonidine, Phenobarbital
- First posted
- 2010-08-05
- Last updated
- 2014-01-06
- Results first posted
- 2014-01-06
- Limitations and caveats
- One of the major limitations to our study was the inability to blind the two groups for the study medications.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Length of Treatment With Neonatal Morphine Sulfate | subjects were followed for the duration of treatment, up to 3 months | |
| Secondary | Total Dose of NMS Used | For the duration of treatment, upto 3 months |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Length of Treatment With Neonatal Morphine Sulfate | subjects were followed for the duration of treatment, up to 3 months | days | MEAN | |
| SECONDARY | Total Dose of NMS Used | For the duration of treatment, upto 3 months | mg/kg | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Length of Treatment With Neonatal Morphine Sulfate | NMS/Clonidine | 18.2 | 95% Confidence Interval 14.9 to 21.5 | days | |
| Length of Treatment With Neonatal Morphine Sulfate | NMS/Phenobarbital | 13.6 | 95% Confidence Interval 11.0 to 16.1 | days | |
| Total Dose of NMS Used | NMS/Clonidine | 5.7 | 95% Confidence Interval 4.7 to 6.8 | mg/kg | |
| Total Dose of NMS Used | NMS/Phenobarbital | 4.6 | 95% Confidence Interval 3.8 to 5.4 | mg/kg |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | NMS/Clonidine | 34 | |
| Overall Study | STARTED | NMS/Phenobarbital | 34 | |
| Overall Study | COMPLETED | NMS/Clonidine | 32 | |
| Overall Study | COMPLETED | NMS/Phenobarbital | 34 | |
| Overall Study | NOT COMPLETED | NMS/Clonidine | 2 | |
| Overall Study | NOT COMPLETED | NMS/Phenobarbital | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Oversedation | Nervous system disorders | NMS/Clonidine | 0 | 34 | 0 |
| other | Oversedation | Nervous system disorders | NMS/Phenobarbital | 3 | 34 | 3 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | NMS/Clonidine | ||
| Total, all-cause mortality | NMS/Phenobarbital | ||
| Total, other adverse events | NMS/Clonidine | 0 | 34 |
| Total, other adverse events | NMS/Phenobarbital | 3 | 34 |
| Total, serious adverse events | NMS/Clonidine | 0 | 34 |
| Total, serious adverse events | NMS/Phenobarbital | 0 | 34 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23949834 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| NMS/Clonidine vs NMS/Phenobarbital: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01175668
GET https://conductscience.org/api/trials/v1/NCT01175668/registered